We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+14.45%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
+$10.1M
Cap. Flow
+$3.44M
Cap. Flow %
2.69%
Top 10 Hldgs %
70.42%
Holding
59
New
8
Increased
11
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$1.1M
2
PHR icon
Phreesia
PHR
+$552K
3
STOK icon
Stoke Therapeutics
STOK
+$534K
4
TXG icon
10x Genomics
TXG
+$392K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$315K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$735K
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$471K
3
BLUE
bluebird bio
BLUE
+$408K
4
TSVT
2seventy bio
TSVT
+$123K
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$91.6K

Sector Composition

Rank Sector Weight
1 Healthcare 95.37%
2 Energy 4.62%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$36M 28.19%
702,298
-13,999
-2% -$735K
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$10.2M 7.96%
77,240
– –
BDSX icon
3
Biodesix
BDSX
$209M
$9.79M 7.66%
267,414
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.38B
$7.53M 5.89%
240,400
– –
PRTA icon
5
Prothena Corp
PRTA
$453M
$6.16M 4.82%
169,574
– –
IMGN
6
DELISTED
Immunogen Inc
IMGN
$5.57M 4.36%
188,000
-2,000
-1% -$39.8K
QDEL icon
7
QuidelOrtho
QDEL
$1.19B
$4.81M 3.76%
65,203
– –
OVV icon
8
Ovintiv
OVV
$16.2B
$3.7M 2.89%
84,200
– –
ELUT icon
9
Elutia
ELUT
$42M
$3.58M 2.8%
1,655,184
– –
PHR icon
10
Phreesia
PHR
$662M
$2.66M 2.08%
114,700
+32,000
+39% +$552K
UTHR icon
11
United Therapeutics
UTHR
$22.7B
$2.42M 1.89%
11,000
– –
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$2.09M 1.63%
25,000
– –
FHTX icon
13
Foghorn Therapeutics
FHTX
$305M
$2.07M 1.62%
320,930
+56,087
+21% +$242K
SILK
14
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$1.94M 1.52%
158,094
+116,800
+283% +$1.1M
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.84M 1.44%
48,448
-22,000
-31% -$471K
MASI
16
DELISTED
Masimo
MASI
$1.79M 1.4%
15,280
– –
HROW icon
17
Harrow
HROW
$1.74B
$1.68M 1.31%
150,000
– –
TXG icon
18
10x Genomics
TXG
$5.55B
$1.68M 1.31%
30,000
+9,000
+43% +$392K
CORT icon
19
Corcept Therapeutics
CORT
$9.72B
$1.62M 1.27%
50,000
– –
ALKS icon
20
Alkermes
ALKS
$8.79B
$1.39M 1.09%
50,000
– –
ETRN
21
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.35M 1.06%
133,050
– –
ATEC icon
22
Alphatec Holdings
ATEC
$1.31B
$1.33M 1.04%
88,000
+8,000
+10% +$95.6K
AXGN icon
23
Axogen
AXGN
$2.12B
$1.18M 0.92%
173,000
– –
STOK icon
24
Stoke Therapeutics
STOK
$1.81B
$1.1M 0.86%
210,000
+125,000
+147% +$534K
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.06B
$1.1M 0.86%
48,000
+10,000
+26% +$175K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Birchview Capital held 59 positions worth $128M, up 8.6% from $118M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q4 2023 filing shows 8 new, 11 increased, 8 reduced and 1 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K. The largest sale was Bristol-Myers Squibb, an estimated $735K.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2023 buy was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K.
  • Birchview Capital added most to Silk Road Medical, Inc. Common Stock in Q4 2023, an estimated $1.1M increase.
  • Birchview Capital's biggest Q4 2023 reduction was Bristol-Myers Squibb, cutting an estimated $735K.
  • Birchview Capital fully exited Nektar Therapeutics in Q4 2023, selling an estimated $16.7K.
  • Birchview Capital's ten largest holdings make up 70% of its $128M portfolio in Q4 2023.
  • Birchview Capital opened 8 new positions and closed 1 in Q4 2023.
  • Birchview Capital's portfolio value rose 8.6% quarter-over-quarter to $128M.

Based on Birchview Capital's 13F filing for Q4 2023, filed 14 Feb 2024.